In contrast to the challenges in producing large-scale preparations of FH for therapeutic use, the large-scale production of antibody-based therapies is well established, which this makes IgG-FH1-5 an attractive potential therapeutic for C3G. The gene discussed is FLNB; the disease is complement 3 glomerulopathy.